This paper provides an overview of recent advances in the use of psychedelics as medicine, along with research needs, safety considerations, and the system capacity and infrastructure needed to support their use.
Searching for Solutions
These results suggest that adolescent and past-year alcohol use may differentially impact habitual responding and attentional bias towards non-drug reward cues.
Most of the sample did not engage with hospital or substance use treatment services after a nonfatal overdose. Negative prior experiences and fear of negative consequences were major barriers in this sample.
This cross-sectional study found divergent age- and sex-specific patterns from 2021 through 2024.
Among adolescents who vaped nicotine and were undergoing substance use disorder treatment, this study observed an abrupt increase in cotinine concentrations from 2023 to 2025.
This pilot trial indicates that the ADS Program is feasible, safe, and potentially effective in supporting self-management of SAC.
THC use disorders seemed to be associated with an increased risk of spirometry-defined SAD and lower small airways spirometric value in this population-based cohort, highlighting the need for screening of THC in patients investigated for SAD.
This study sought to characterize the biosignatures of craving through the measurement of HRV using a combination of ECG monitoring and EMA in individuals in the first year of a current AUD recovery attempt.
These findings confirm previous results among non–treatment seekers with less severe AUD and suggest that continued development of semaglutide for AUD is warranted.
Learn how having psychiatric pharmacists on the team impact child and adolescent psychiatric care.
No summary available
The harm reduction toolkit was recently updated by AAPP member Michelle Geier. Content focuses on defining harm reduction, harm reduction services for individuals and communities, and the identification of potential barriers to pharmacist engagement in harm reduction practices. AAPP members receive complimentary, continuous access to toolkits. Non-members can purchase for a fee for a period of 3 months.
No summary available
No summary available
HHS and the Department of Veterans Affairs operate three major national support hotlines: the 988 Suicide & Crisis Lifeline (988 Lifeline), the Veterans Crisis Line, and the National Maternal Mental Health Hotline. According to a recent Government Accountability Office report covering fiscal year 2025, overall contact volume across all three hotlines generally increased throughout the year.
JAMA Psychiatry article that evaluated racial and ethnic disparities in retention in buprenorphine and methadone treatment among pregnant US females with OUD.
This living umbrella review synthesized and evaluated the certainty of all available meta-analytic evidence on treatments for bipolar disorder across age groups, mood phases, and outcomes.
New SAMHSA Publication! This policy paper presents current evidence on AI and mental health services, and examines what is known or proposed in a rapidly evolving AI enterprise. Based on this information, the paper provides considerations for policymakers as they govern responsibly advancing AI into mental health and substance use disorder services.
Findings from this study suggest that Oregon’s state-regulated psilocybin services are generally safe and associated with improvements in mental health symptoms.
AAPP submitted comments on CMS’s CY 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule, supporting CMS’s proposed updates to payment rates for Intensive Outpatient Programs (IOPs) and Partial Hospitalization Programs (PHPs) by using the most recent available claims and cost data.
The CMS Healthcare Advisory Committee (HAC) is charged with developing recommendations to improve the U.S. healthcare system, including addressing healthcare access and workforce challenges. In preparation for its next meeting, AAPP submitted comments urging the HAC to support policies that allow for greater use of psychiatric pharmacists to help address behavioral health workforce shortages and expand access to mental health and substance use disorder care.
ASAM is recruiting experts to help develop updated clinical guidance on integrating tobacco use disorder interventions into addiction treatment. Opportunities are available on the writing group, education faculty team, and as field reviewers. Applications are due August 12.
Fewer adolescents reported using tobacco, alcohol, marijuana, and binge drinking.
Risks rose through year 5 in youths, but were seen after even just 1 year.
Triple reuptake inhibitor centanafadine is indicated for patients ages 6 years and older.